Adaptive Biotechnologies (ADPT) Income from Continuing Operations (2018 - 2026)
Adaptive Biotechnologies (ADPT) posted Income from Continuing Operations of 53004000.0 for Q1 2026, down 267.09% sequentially from 14439000.0 in Q4 2025, and down 77.12% YoY from 231689263.8 in Q1 2025.
Adaptive Biotechnologies (ADPT) Income from Continuing Operations (2018 - 2026) Analysis & Trends
Adaptive Biotechnologies has reported Income from Continuing Operations for 9 years, with the latest figure at 53004000.0 in Q1 2026.
- Quarterly Income from Continuing Operations fell 77.12% year-over-year to 53004000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 181154000.0 (down 30.07% YoY) and the FY2025 annual result came in at 61979000.0, up 61.67% from the prior year.
- Income from Continuing Operations retreated to 53004000.0 in Q1 2026 per ADPT's latest filing, from 14439000.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 9545000.0 in Q3 2025 and troughed at 208686000.0 in Q1 2022.
- A 5-year average of 56268823.53 and a median of 48240000.0 in 2024 frame the typical range for Income from Continuing Operations.
- The widest YoY moves for Income from Continuing Operations: up 129.74% in 2025, down 166.51% in 2025.
- Over 5 years, Income from Continuing Operations stood at 38884000.0 in 2022, then tumbled by 78.65% to 69467000.0 in 2023, then jumped by 55.37% to 31001000.0 in 2024, then surged by 53.42% to 14439000.0 in 2025, then plunged by 267.09% to 53004000.0 in 2026.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 53004000.0, 14439000.0, and 9545000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 234.15 Bn | 230.09 Bn | 8.34 Bn | 1.76 Bn |
| 2 | Danaher | 152.10 Bn | 147.75 Bn | 3.61 Bn | 870.00 Mn |
| 3 | Natera | 48.48 Bn | 47.38 Bn | 486.15 Mn | -66.93 Mn |
| 4 | Agilent Technologies | 44.35 Bn | 42.55 Bn | 990.00 Mn | 339.00 Mn |
| 5 | Iqvia Holdings | 43.68 Bn | 41.60 Bn | 1.44 Bn | 241.00 Mn |
| 6 | Idexx Laboratories | 43.02 Bn | 42.83 Bn | 779.09 Mn | 338.41 Mn |
| 7 | Illumina | 34.39 Bn | 33.22 Bn | 770.00 Mn | 207.00 Mn |
| 8 | Mettler Toledo International | 28.29 Bn | 28.24 Bn | 650.22 Mn | 232.90 Mn |
| 9 | Labcorp Holdings | 27.51 Bn | 27.37 Bn | 1.11 Bn | 299.10 Mn |
| 10 | Adaptive Biotechnologies | 4.23 Bn | 3.89 Bn | 51.39 Mn | -16.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -16.21 Mn |
| Mar 31, 2026 | -20.02 Mn |
| Dec 31, 2025 | -13.58 Mn |
| Sep 30, 2025 | 9.55 Mn |
| Jun 30, 2025 | -25.59 Mn |
| Mar 31, 2025 | -29.83 Mn |
| Dec 31, 2024 | -33.72 Mn |
| Sep 30, 2024 | -32.10 Mn |
| Jun 30, 2024 | -46.25 Mn |
| Mar 31, 2024 | -47.53 Mn |
| Dec 31, 2023 | -69.47 Mn |
| Sep 30, 2023 | -50.33 Mn |
| Jun 30, 2023 | -47.81 Mn |
| Mar 31, 2023 | -57.70 Mn |
| Dec 31, 2022 | -40.17 Mn |
| Sep 30, 2022 | -45.32 Mn |
| Jun 30, 2022 | -52.08 Mn |
| Mar 31, 2022 | -62.80 Mn |
| Dec 31, 2021 | -61.36 Mn |
| Sep 30, 2021 | -56.00 Mn |